Kura Oncology to Host Virtual Investor Event on December 5, 2020

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a review of the Company's oral, potent and selective menin inhibitor, KO-539, following the oral presentation of preliminary clinical data at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature members of the Kura management team along with two of the investigators from KOMET-001, an ongoing Phase 1/2A clinical trial of KO-539. The virtual event will take place at 2:00 p.m. ET / 11:00 a.m. PT on Saturday, December 5, 2020.

A live video webcast of the event will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay available shortly after the conclusion of the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company's pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia. For additional information about Kura, please visit the Company's website at www.kuraoncology.com.

Contacts

Company:

Pete De Spain

Vice President, Investor Relations &

Corporate Communications

(858) 500-8803

pete@kuraoncology.com

Investors:

Robert H. Uhl

Managing Director

Westwicke ICR

(858) 356-5932

robert.uhl@westwicke.com

Media:

Jason Spark

Managing Director

Canale Communications

(619) 849-6005

jason@canalecomm.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!